newsfilter
← Latest News
Business Wire·

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

  • bioAffinity Technologies (NASDAQ: BIAF, BIAFW) announced a collaboration with Pictor, Inc. to develop & commercialize next-generation diagnostic tests for asthma & COPD.
  • The partnership integrates bioAffinity's flow cytometry expertise with Pictor's targeted proteomic platform to analyze immune cell populations & cytokine profiles associated with airway inflammation.
  • The collaboration aims to increase laboratory throughput, reduce operating costs, & lower testing complexity compared to traditional single-analyte methods.
  • Tests under development will build on bioAffinity's proprietary sputum analysis approach, currently used in its commercially available CyPath Lung test.
  • bioAffinity will own the intellectual property for the new asthma & COPD tests, while Pictor retains its existing IP & owns new inventions related to its proteomic platform.
  • The new diagnostics are expected to launch initially as Laboratory Developed Tests (LDTs) under the Clinical Laboratory Improvement Amendments (CLIA).
  • The testing protocol enables precision medicine by identifying specific inflammatory pathways to help physicians match patients with effective targeted therapies & biologics.
  • Asthma & COPD affect over 40 million Americans & 650 million people worldwide, with the global therapeutics market projected to exceed $108 billion in 2026 & $155 billion by 2030.
  • Pictor, Inc. is led by CEO Jamie Platt, PhD, who joined bioAffinity's Board of Directors in 2023 & previously led diagnostic company acquisitions valued at nearly $1 billion.
  • Pictor operates globally with headquarters in Carlsbad, California, & holds an IP portfolio including 16 patents, five pending, & seven registered trademarks.